Landmark Multiple Myeloma Trials: Chronological Overview with Detailed Regimens
The treatment of multiple myeloma has evolved dramatically through landmark trials that established novel agent-based combinations as superior to traditional chemotherapy, with the most recent evidence supporting daratumumab-containing quadruplet regimens for transplant-eligible patients.
Era 1: Establishing Novel Agents in Elderly/Non-Transplant Patients (Early 2000s-2010s)
Thalidomide Era
MPT (Melphalan-Prednisone-Thalidomide) Trials established the first novel agent combination for elderly patients 1. These phase III randomized trials demonstrated that adding thalidomide to the traditional MP backbone improved response rates and became an EMA-approved standard of care 1.
Regimen details:
- Melphalan: oral dosing with prednisone
- Thalidomide: added to MP backbone
- Clinical significance: Superior response rates vs MP alone, though survival advantage was not definitively established 1
Bortezomib Era
VMP (Bortezomib-Melphalan-Prednisone) Trials represented the proteasome inhibitor breakthrough 1. Phase III randomized trials established VMP as a category 1, level A recommendation for elderly patients.
Regimen details:
- Bortezomib: combined with melphalan and prednisone
- Clinical significance: EMA-approved, became co-standard with MPT for non-transplant patients 1
Other Notable Elderly Patient Trials
CTD (Cyclophosphamide-Thalidomide-Dexamethasone) was compared to MP and showed superior response rates but no clear survival advantage 1. This highlights an important caveat: response rates don't always translate to survival benefit.
MPR (Melphalan-Prednisone-Lenalidomide) was evaluated in prospective randomized studies versus MP but was not superior with fixed cycles 1. This triplet is not approved and not standard of care 1.
Era 2: Transplant-Eligible Patients - Induction Evolution (2000s-2010s)
VAD Replacement
Bortezomib-Dexamethasone vs VAD trials established that bortezomib-dexamethasone was superior to classical VAD (vincristine, adriamycin, high-dose dexamethasone) for induction before ASCT 1. This became the backbone for modern induction therapy.
Three-Drug Induction Combinations
VTD (Bortezomib-Thalidomide-Dexamethasone) Trials - Three prospective studies demonstrated VTD superiority over TD or bortezomib-dexamethasone alone 1.
Other three-drug regimens evaluated in phase II trials 1:
- PAD/DVD: Bortezomib + doxorubicin + dexamethasone
- RVD: Lenalidomide + bortezomib + dexamethasone
- VCD: Bortezomib + cyclophosphamide + dexamethasone
Key recommendation: Three-drug combinations including at least bortezomib and dexamethasone became standard of care before ASCT, with 3-4 courses recommended before stem cell collection 1.
Transplant Conditioning
Melphalan 200 mg/m² IV was established as the standard preparative regimen before ASCT 1.
Tandem Transplant Trials
HOVON 65-GMMG HD4 Trial evaluated tandem vs single ASCT in the bortezomib era 1. OS was better in the GMMG group (tandem ASCT) versus HOVON (single ASCT), though the trial wasn't powered for this comparison 1. The benefit of tandem ASCT was particularly observed in patients not reaching VGPR after first ASCT 1.
Era 3: Lenalidomide Maintenance (2010s)
Phase III randomized trials demonstrated that maintenance therapy with IMiDs (lenalidomide or thalidomide) following ASCT improved outcomes 1. However, there's an increased risk for secondary cancers, especially with lenalidomide maintenance following transplant 2. The benefits versus risks should be discussed with patients 2.
Current maintenance recommendations 2:
- Preferred: Lenalidomide (category 1)
- Other recommended: Carfilzomib/lenalidomide, Daratumumab/lenalidomide
- Useful in certain circumstances: Bortezomib ± lenalidomide, Ixazomib (category 2B)
- Two-drug maintenance recommended for high-risk MM 2
Era 4: Daratumumab Revolution (Late 2010s-2020s)
D-VCd (Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone)
LYRA Study (2019) 3 evaluated D-VCd in both newly diagnosed and relapsed MM in a US community setting.
Regimen details:
- Bortezomib: 1.5 mg/m²
- Cyclophosphamide: 300 mg/m²
- Dexamethasone: 40 mg weekly
- Daratumumab: 16 mg/kg IV (split-first dose in Cycle 1)
- Induction: 4-8 cycles
- Maintenance: ≤12 daratumumab doses monthly
Results in NDMM patients:
- ≥VGPR after 4 cycles: 44% (primary endpoint)
- ORR after 4 cycles: 79%
- ≥VGPR at end of induction: 56%
- 12-month PFS rate: 87%
- Infusion reactions: 54% (primarily first dose, mostly mild)
- Median first 2 infusion times: 4.5 and 3.8 hours
MASTER Trial (2023) - MRD-Adapted Therapy
MASTER Trial 4 was a groundbreaking multicentre, single-arm, phase 2 trial using Dara-KRd with MRD-guided treatment cessation.
Regimen details (Dara-KRd):
- Daratumumab: 16 mg/kg IV on days 1,8,15,22
- Carfilzomib: 56 mg/m² IV on days 1,8,15
- Lenalidomide: 25 mg PO on days 1-21
- Dexamethasone: 40 mg PO/IV on days 1,8,15,22
- Cycle length: 28 days
Study design:
- 4 cycles induction → ASCT → up to 2 consolidation phases
- MRD assessed by NGS after each phase
- Treatment cessation: Two consecutive MRD-negative results (<10⁻⁵)
- MRD-SURE: Observation with MRD surveillance after stopping treatment
Results (n=123, median follow-up 42.2 months):
- 96/118 (81%) reached MRD <10⁻⁵
- 84 (71%) reached MRD-SURE and stopped treatment
- 61 patients (52% of MRD-evaluable, 73% of MRD-SURE) remain therapy-free and MRD-negative
36-month PFS by risk:
- No HRCAs: 88%
- One HRCA: 79%
- ≥2 HRCAs: 50% (ultra-high-risk)
24-month cumulative incidence of progression from treatment cessation:
- No HRCAs: 9%
- One HRCA: 9%
- ≥2 HRCAs: 47%
Safety: Most common grade 3-4 AEs were neutropenia (35%), lymphopenia (23%), hypertension (11%)
Critical insight: Patients with ≥2 HRCAs (ultra-high-risk) had unsatisfactory outcomes and should be prioritized for trials with novel mechanisms 4.
PERSEUS Trial (2024) - Current Standard
PERSEUS 5 is the most recent and highest quality phase 3 trial establishing the current standard for transplant-eligible NDMM.
Study design:
- 709 transplant-eligible NDMM patients randomized
- D-VRd group: Subcutaneous daratumumab + VRd induction/consolidation + lenalidomide maintenance
- VRd group: VRd induction/consolidation + lenalidomide maintenance alone
Regimen details:
- Subcutaneous daratumumab added to standard VRd
- Followed by lenalidomide maintenance
Results (median follow-up 47.5 months):
- Primary endpoint (PFS): HR 0.42 (95% CI 0.30-0.59; P<0.001)
- 48-month PFS: 84.3% (D-VRd) vs 67.7% (VRd)
- Complete response or better: 87.9% vs 70.1% (P<0.001)
- MRD-negative status: 75.2% vs 47.5% (P<0.001)
- MRD-negative ≥12 months: 64.8% vs 29.7%
- MRD-negative at 10⁻⁶ sensitivity: 65.1% vs 32.2%
Safety:
- Grade 3-4 neutropenia: 62.1% vs 51.0%
- Grade 3-4 thrombocytopenia: 29.1% vs 17.3%
- Serious AEs: 57.0% vs 49.3%
- Deaths: 34 (D-VRd) vs 44 (VRd)
Clinical significance: This trial crossed the prespecified stopping boundary and represents the strongest current evidence for adding subcutaneous daratumumab to VRd in transplant-eligible NDMM 5.
GRIFFIN Trial (Final Analysis)
GRIFFIN final analysis 2 supported D-VRd benefits with:
- Stringent CR: 67% vs 48% (VRd)
- 4-year PFS: 87.2% vs 70% (HR 0.45; 95% CI 0.21-0.95)
Era 5: Relapsed/Refractory Disease Trials
TOURMALINE-MM2 (2021) - Ixazomib
TOURMALINE-MM2 6 evaluated oral ixazomib in transplant-ineligible NDMM.
Regimen details:
- Ixazomib: 4 mg (reduced to 3 mg after 18 cycles)
- Plus lenalidomide-dexamethasone (Rd)
- Treatment duration: Until progression/toxicity
- After 18 cycles: dexamethasone discontinued, reduced-dose ixazomib (3 mg) + lenalidomide (10 mg)
Results (n=705, median follow-up ~54 months):
- Median PFS: 35.3 vs 21.8 months (HR 0.830; P=0.073)
- PFS benefit: 13.5 months (clinically meaningful despite not meeting statistical significance)
- CR rate: 26% vs 14% (OR 2.10; P<0.001)
- ≥VGPR: 63% vs 48% (OR 1.87; P<0.001)
- High-risk cytogenetics subgroup PFS: 23.8 vs 18.0 months (HR 0.690; P=0.019)
Safety:
- Grade ≥3 TEAEs: 88% vs 81%
- Serious TEAEs: 66% vs 62%
- Discontinuation due to TEAEs: 35% vs 27%
Clinical significance: Provides an all-oral triplet option for patients who can benefit from this approach 6.
FOCUS Trial (2017) - Carfilzomib Monotherapy
FOCUS 7 compared carfilzomib monotherapy vs low-dose corticosteroids ± cyclophosphamide in heavily pretreated RRMM.
Regimen details:
- Carfilzomib: 10-min IV infusion
- 20 mg/m² on days 1-2 of cycle 1
- 27 mg/m² thereafter
- Control: Dexamethasone 84 mg (or equivalent) ± cyclophosphamide 1400 mg
- Cycle length: 28 days
Results (n=315, median 5 prior regimens):
- Median OS: 10.2 vs 10.0 months (HR 0.975; P=0.4172)
- ORR: 19.1% vs 11.4%
- PFS similar between groups
Clinical significance: Single-agent carfilzomib showed similar OS to active doublet in heavily pretreated patients, establishing its activity but not superiority as monotherapy 7.
Pomalidomide Trials (2010s)
MM-003 Trial 8 was the pivotal phase III trial establishing pomalidomide.
Regimen details:
- Pomalidomide: 4 mg PO days 1-21 of 28-day cycles
- Low-dose dexamethasone: vs high-dose dexamethasone alone
- Population: Relapsed MM refractory to both lenalidomide and bortezomib
Results (n=455, median follow-up 10 months):
- Median PFS: 4.0 vs 1.9 months (HR 0.45; P<0.0001)
- Median OS: 12.7 vs 8.1 months (HR 0.74; P=0.0285)
FDA approval: For patients with ≥2 prior therapies including lenalidomide and bortezomib, with progression on or within 60 days of last therapy 8.
Phase IIIb trial 8 (n=604):
- Median PFS: 4.2 months
- Median OS: 11.9 months
- Consistent results regardless of prior lenalidomide or bortezomib
Phase II dose-finding studies 8:
- 2 mg vs 4 mg daily evaluated
- ORR: 35-49% across cohorts
- Median OS: 14.9 months
- Myelosuppression most common toxicity
Era 6: Emerging Therapies (2020s-Present)
Selinexor Combinations
Phase I/II trial 8 evaluated selinexor/pomalidomide/dexamethasone:
- 65 patients enrolled (median 3 prior lines)
- ORR in phase II cohort (n=20): 65%
Bispecific Antibodies
IMWG Consensus Guidelines (2024) 9 provide recommendations for T-cell-engaging bispecific antibodies, representing the newest class of immunotherapies with unique mechanisms and toxicities requiring specialized management.
EXCALIBER-RRMM (Ongoing)
Phase III trial 10 evaluating iberdomide (CELMoD agent) + daratumumab + dexamethasone in early-line RRMM (1-2 prior lines). This represents next-generation immunomodulatory therapy with greater tumoricidal and immune-stimulatory effects than traditional IMiDs.
Key Clinical Pearls and Pitfalls
Common pitfalls to avoid:
Response rates ≠ survival benefit: CTD showed superior response rates vs MP but no clear survival advantage 1. Always prioritize OS and PFS data.
Ultra-high-risk disease (≥2 HRCAs): Standard quadruplet therapy insufficient; these patients need novel mechanisms early 4.
Secondary malignancy risk: Lenalidomide maintenance increases secondary cancer risk; discuss benefits vs risks 2.
MRD-guided therapy: MASTER trial demonstrates feasibility of treatment cessation in MRD-negative patients, but ultra-high-risk patients still progress 4.
Infusion reactions with daratumumab: Occur in ~54% (mostly first dose, predominantly mild); split-first dosing feasible 3.
Maintenance duration: Two-drug maintenance specifically recommended for high-risk MM 2.
Current treatment algorithm based on evidence:
Transplant-eligible NDMM:
- Standard: D-VRd induction → ASCT → consolidation → lenalidomide maintenance 5, 2
- Alternative: Consider MRD-adapted approach (Dara-KRd) with treatment cessation for sustained MRD negativity 4
- Ultra-high-risk (≥2 HRCAs): Prioritize clinical trials with novel mechanisms 4
Transplant-ineligible NDMM:
- First options: MPT or VMP 1
- Second option: Bendamustine-prednisone (for neuropathy) 1
- All-oral option: Ixazomib-Rd for appropriate patients 6
Relapsed/refractory: